A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study) A Turkish Oncology Group Study

Abali, Huseyin; YALÇIN, ŞUAYİB; Onal, Huseyin; Dane, Faysal; Oksuzoglu, Berna; ÖZDEMİR, NURİYE; Mertsoylu, Huseyin; ARTAÇ, MEHMET; Camci, Celaletdin; KARABULUT, BÜLENT; Basal, Fatma; Budakoglu, Burcin; Sendur, Mehmet; Goktas, Burce; Ozdener, Fatih; Baygul, Arzu

doi:10.1097/coc.0000000000000825

A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study) A Turkish Oncology Group Study

Abali H., YALÇIN Ş., Onal H. C., Dane F., Oksuzoglu B., ÖZDEMİR N., ...Daha Fazla

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, cilt.44, sa.7, ss.301-307, 2021 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 44 Sayı: 7
Basım Tarihi: 2021
Doi Numarası: 10.1097/coc.0000000000000825
Dergi Adı: AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, BIOSIS, EMBASE, MEDLINE
Sayfa Sayıları: ss.301-307
Hacettepe Üniversitesi Adresli: Evet

Özet

Background: Trastuzumab prolonged the overall survival in patients with advanced gastric cancer with human epidermal growth factor receptor 2 (HER2) overexpression in combination with chemotherapy. In this phase II open-label prospective study, the tolerability and safety of trastuzumab with chemotherapy, and chemoradiotherapy for curatively resected patients with HER2-positive gastric carcinoma was investigated.